Unveiling the Scientific Landscape and Trends of Cutaneous Immune-Related Adverse Events: A Bibliometric Analysis.
With the widespread use of immune checkpoint inhibitors (ICIs) in cancer treatment, cutaneous immune-related adverse events (cirAEs) have attracted increasing attention.
APA
Zhong D, Shi C (2026). Unveiling the Scientific Landscape and Trends of Cutaneous Immune-Related Adverse Events: A Bibliometric Analysis.. Cureus, 18(3), e105013. https://doi.org/10.7759/cureus.105013
MLA
Zhong D, et al.. "Unveiling the Scientific Landscape and Trends of Cutaneous Immune-Related Adverse Events: A Bibliometric Analysis.." Cureus, vol. 18, no. 3, 2026, pp. e105013.
PMID
41970141
Abstract
With the widespread use of immune checkpoint inhibitors (ICIs) in cancer treatment, cutaneous immune-related adverse events (cirAEs) have attracted increasing attention. This bibliometric analysis reveals that research on cirAEs has grown steadily, with enhanced global collaboration. The focus has progressively shifted from early studies on specific agents and conditions toward severe cutaneous adverse reactions, diverse cancer types, and systemic clinical management strategies. This evolution reflects a deeper investigation into underlying mechanisms and a heightened emphasis on personalized treatment approaches, thus offering insights for future interdisciplinary research aimed at optimizing clinical management and improving treatment safety.
같은 제1저자의 인용 많은 논문 (5)
- Improving Lung Cancer Screening Selection: A Comparative Analysis of Risk Models and Traditional Criteria in a Western European General Population.
- KCTD1 stabilizes c-Myc to upregulate PD-L1 and suppress anti-tumor immunity in hepatocellular carcinoma.
- Prognostic Value of the Ratio of Interleukin-2 and Interleukin-10 in Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Therapy.
- Preoperative TACE with PD-1 inhibitors and TKIs in beyond "up-to-seven" hepatocellular carcinoma: a propensity score matched analysis.
- TYROBP facilitates metastatic progression in pancreatic cancer through CTSZ-driven glycolytic rewiring and macrophage recruitment.